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Abstract This short review summarizes developments
and achievements made during the last few years in spinal
neurology and includes all relevant papers published in the
Journal of Neurology during this time. A focus of the
review concerns the debate about the significance of
translational medicine in spinal cord injury with the
introduction of new drugs directed to achieve some spinal
cord repairs.
Keywords Spinal cord repair  Myelopathy  Babinski
sign  Neuroplasticity  Spinal cord ischemia
Introduction
Para-tetraplegia is the consequence of damage to the spinal
cord from a trauma or non-traumatic (inflammatory, vas-
cular, neoplastic or metabolic) origin with an acute or
chronic-progressive appearance. The neurological deficits
include motor, sensory and autonomic functions. The
consequences are motor (spastic para-tetraplegia or flaccid
paraparesis due to a cauda lesion), sensory (spinal sensory
level with hyperaesthesia—algesia or anesthesia–algesia
below the level of lesion) and autonomic (neurogenic
bladder- bowel-, sexual-, and circulatory disturbances)
dysfunction. Therefore, below the level of spinal cord
injury (SCI), complex clinical disturbances exist. The
severity of deficits depends on the level and completeness
of the spinal cord lesion.
This review summarises progress in spinal cord neu-
rology and will focus on trauma and pathology concerning
primarily the spinal cord, i.e., it will exclude the spinal
cord involvement in systemic diseases as, for example,
autoimmune or genetically determined diseases which also
can involve the spinal cord.
After dealing with some aspects of spinal cord neurol-
ogy, this review will focus on a discussion concerning
spinal cord repair and the actual state of regeneration-
inducing therapies cf. [1]. Surprisingly, in specialized
Journals such as ‘Spinal Cord’, the subject of spinal cord
neurology plays only a minor role e.g., [2].
Actual diagnostic approaches
The long-term course of non-traumatic acute/subacute
myelopathies is important to assess in follow-up examin-
ations for recognizing etiology and prediction of outcome
[3]. It is reported that an unfavorable outcome can be
expected when the initial symptoms are severe, the lesion
is centrally located in the spinal cord (MRI) and the eti-
ology is neuromyelitis optica or part of a systemic disease.
Over half of the patients subsequently develop multiple
sclerosis, and in one-third the etiology at the end of the
follow-up differs from that suspected initially. An intra-
medullary spinal cord hemorrhage is a quite uncommon
cause of myelopathy and can present in an acute, subacute,
or chronic fashion. Spinal vascular malformations (e.g.,
cavernomas) are the most common cause of such a hem-
orrhage [4].
The question concerning the presence or absence of the
Babinski sign in severe spinal cord injuries is of clinical
relevance. In only about half of the subjects suffering a
complete SCI is the Babinski sign positive [5]. While the
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occurrence of the Babinski sign does not depend on the
level of lesion, it is associated with high spastic muscle
tone. In contrast, subjects with a negative Babinski sign
show a low level, or absent, muscle tone. The low muscle
tone can be attributed to peripheral nerve damage, mye-
lomalacia below the level of lesion, or Baclofen therapy.
The clinical and imaging features in spinal cord ische-
mia are shown to be frequently connected with aortic dis-
ease and associated with a vertebral body infarction [6].
Concomitant spinal cord and vertebral body infarctions are
frequently located in the thoracolumbar region. The neu-
rological deficit in most of these subjects has a poor out-
come, especially concerning their walking ability.
Rare cases of spinal cord damage due to sarcoidosis [7]
and secondary to psoriatic arthritis [8] have been reported.
Spinal cord sarcoidosis can successfully be detected
using18F-FDG PET uptakes, an abnormality that resolves
following clinical improvement with treatment. Acute
transverse myelitis due to psoriatic arthritis is considered to
be a variant of rheumatic arthritis with the rheumatoid
factor being negative.
Two widely unknown clinical signs can be of diagnostic
relevance in spinal cord pathology, Beevor’s sign [9] and
the painful neck rotation sign [10]. In Beevor’s sign, an
upward deflection of the umbilicus on flexion of the neck is
the due to the paralysis of the inferior portion of the ab-
dominis muscle. This condition can be caused by a SCI at or
below the level of Th10 or, alternatively, by a facioscapu-
lohumeral muscular dystrophy [9]. However, this sign is
reported not to be as sensitive as previously assumed.
In patients suffering cervico-occipital pain, a painful and
limited neck rotation may be indicative of the crowned
dens syndrome, defined as acute neck pain due to deposi-
tion of crystals surrounding the odontoid process [10]. In
these cases computed tomography shows mottled calcifi-
cation around the odontoid process.
Therapeutic approaches
Novel therapies in spinal cord damage are rare. The
administration of Erythropoietin (EPO) in SCI as a neu-
roprotective drug, blocking apoptosis, is discussed [11].
There are promising preclinical results. However, a clear
demonstration of an effective pharmacological treatment is
yet lacking. Thus, at present no therapy is available to
directly limit spinal cord damage after trauma.
In incomplete SCI subjects, the exploitation of innate
neuronal plasticity using a functional training programme
is well established [12]. Neuroplasticity plays an important
role in the neurorehabilitation even of elderly SCI subjects
[13]. The progress made in this field concerns the definition
of essential factors for the effectiveness and optimization
of such a functional training. For example, it has become
evident that, for an effective locomotor training of
incomplete SCI subjects, the activation of load-and hip
joint related afferent input is mandatory [12]. During the
last years the application of advanced versions of robotic
devices have been successfully established in functional
training programmes. Such devices have the advantage that
they allow for longer training times and can improve the
training through virtual reality and feedback information
technology [14].
The use of intrathecal baclofen therapy is well estab-
lished in chronic spinal cord injured subjects. In a recent
study, the incidence and management of tolerance in
intrathecal baclofen therapy over a follow-up time of about
3 years is discussed [15]. On average the baclofen dose
increases over the first 18 months and than stabilizes. Only
about 20% of patients develop tolerance and about a third
of patients require surgical revision of the pump system
because of mechanical failures. Nevertheless, overall this
therapy is suggested to be effective and safe, including
over the long term.
Regeneration-inducing therapies: promises
and challenges
For several years now, data from rodent studies indicate the
feasibility of achieving partial repair of neuronal damage
after a severe SCI. However, the success achieved in animal
experiments often cannot be replicated in humans. In
rodents, for example, the application of regeneration-facil-
itating olfactory ensheathing cells led to partial repair of
spinal cord damage [16, 17], while, in contrast, this approach
(olfactory mucosal autografts) had no [18–20] or only little
[21] effect on the neurological deficits in humans suffering
severe SCI. During the last few years though, we have
become increasingly aware of the problems associated with
such translational studies [1, 22]. There are several aspects of
the complexity in this field which have to be considered.
First, the frequently used transection animal model for
an SCI fits poorly with the human situation. In humans a
contusional lesion with bleeding and edema usually
extends over several segments of the spinal cord. There-
fore, any functionally effective regeneration would cer-
tainly be harder to administer with benefit under these
circumstances compared to the artificially induced experi-
mental spinal tract transection.
Second, thoracic lesions are usually studied in animal
models, whereas injury to the cervical cord (and second to
the lumbar cord) is most common in humans [23]. However,
in cervical and lumbar spinal cord contusions, the spinal
damage concerns not only tract fibres, but also the motor
neurones and their nerve roots over two or three segments
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which supply innervation to the arm and leg muscles,
respectively. According to rodent experiments, up to 40%
of the motor deficits might be attributed to the peripheral
nervous system [24], and this would not be helped by an
intervention directed at spinal tract regeneration.
Third, while acute animal models used for regeneration-
inducing therapies are well established, limited experience
exists with subacute and chronic SCI. However, new
interventional therapies are frequently applied to chronic
spinal cord injured subjects in order to have a stable clin-
ical condition [18, 20, 21], and this typically occurs about a
year after the initial trauma [23]. Studies with chronic,
complete, SCI subjects during the last few years have
provided evidence to suggest that the function of spinal
neuronal circuits is impaired [25, 26]. However, a preser-
vation of the function of spinal neuronal circuits below the
level of lesion, is an essential prerequisite for the success of
any kind of regeneration-inducing therapy [22]. Thus, even
if regeneration of tract fibres is achieved, this may not
necessarily be matched by a functional improvement. In
addition, in chronic SCI, demyelination around the cavities
[27] and scar formation [28] might prevent a significant
amount of regeneration and so for most current studies,
early intervention is recommended [22].
Fourth, most studies on regeneration-inducing inter-
ventions are applied in motor complete SCI subjects [18,
20, 21], because sensorimotor incomplete SCI subjects
show a good spontaneous recovery of function [23, 29]. In
a great number of these motor complete SCI subjects it has
to be assumed that no more tissue bridges exist at the lesion
site. However, for most of the presently available regen-
eration-inducing therapies (e.g., application of Nogo-anti-
bodies) such tissue bridges are a prerequisite for successful
tract fibre regeneration.
In any case, only a combination of regeneration-induc-
ing therapies with functional training will allow for a better
outcome of function, as it is only through this approach that
appropriate connections with neuronal circuits can be
established by the regenerating fibres.
In conclusion, although there has been much progress
in translational medicine to repair the partially injured
spinal cord, there still are challenges and open questions
to be resolved before we can expect a successful appli-
cation of regeneration-inducing therapies in SCI subjects.
Nevertheless, by increasing our knowledge about the
(dys)function of neuronal circuits in chronic SCI subjects,
appropriate counter measures can hopefully be developed.
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